Core Viewpoint - The A-share market is experiencing a strong bullish sentiment, with the total market value surpassing 100 trillion yuan for the first time in history on August 18, 2025, and the Shanghai Composite Index reaching a nearly ten-year high [1][2]. Group 1: Market Trends - Analysts increasingly view the current market rally as the second wave of a bull market, following the "9·24" rally from last year [2]. - Historical patterns indicate that identifying the "main track" during a bull market can yield substantial and sustainable investment returns, as seen in previous bull markets where leading sectors significantly outperformed the index [3]. Group 2: Investment Opportunities - The upcoming phase of the market is expected to benefit from strong sector-specific ETFs, such as the broker ETF (512000) and financial technology ETF (159851), which provide convenient and low-cost investment options [5]. - The choice of investment sectors ("what to invest in") is likely to be more critical than the timing of entry ("when to invest") in the anticipated bull market 2.0 [6]. Group 3: Bull Market Characteristics - The characteristics of bull market 2.0 are becoming evident, with a generally optimistic outlook among industry insiders [7]. - Wang Sheng, a prominent strategist, predicts that this bull market will be prolonged, driven by the rising international influence of China and the competitiveness of its manufacturing sector [9]. Group 4: Key Sectors - The brokerage sector is expected to lead the bull market, historically referred to as the "bull market flag bearer," with significant outperformance during previous bull runs [11]. - The financial technology sector is also positioned to perform well, benefiting from increased spending by financial institutions and the expansion of innovative services [16]. Group 5: Innovation in Pharmaceuticals - The innovative pharmaceutical sector, particularly in Hong Kong, is likely to emerge as a leading sector in the current market rally, with the Hong Kong Stock Connect Innovative Drug Index rising by 130.74% over the past year [17]. - The sector's growth is supported by a renewed recognition of domestic innovative drug companies by international firms, leading to increased valuations and investment opportunities [21].